

Address to: Assistant Commissioner for Patents

Box CPA

Washington, DC 20231

22/Regunder 1.114

CONTINUED PROSECUTION APPLICATION (CPA) REQUEST TRANSMITTAL

This is a request for a **continuation** application under 37 CFR §1.53(d) (continued prosecution application (CPA)) of prior Application No. 09/341,821, filed on September 1, 1999.

RECEIVE

Applicant:

MICHAEL WARING, ELIZABETH JACQUES

SEP 1 6 2002

Title:

MULTI-DOSE WOUND GEL

TECH CENTER 1600/2900

NOTES

FILING QUALIFICATIONS: The prior application identified above must be a nonprovisional application that is either: (1) complete as defined by 37 CFR §1.51(b), or (2) the national stage of an international application in compliance with 35 USC §371. A Notice will be placed on a patent issuing from a CPA, except for reissues and designs, to the effect that the patent issued on a CPA and is subject to the twenty-year patent term provisions of 35 USC §154(a)(2). Therefore, the prior application of a CPA may have been filed before, on or after June 8, 1995.

C-I-P NOT PERMITTED: A continuation-in-part application cannot be filed as a CPA under 37 CFR §1.53(d), but must be filed under 37 CFR §1.53(b).

EXPRESS ABANDONMENT OF PRIOR APPLICATION: The filing of this CPA is a request to expressly abandon the prior application as of the filing date of the request for a CPA. 37 CFR §1.53(b) must be used to file a continuation, divisional, or continuation-in-part of an application that is not to be abandoned.

ACCESS TO PRIOR APPLICATION: The filing of this CPA will be construed to include a waiver of confidentiality by the applicant under 35 USC §122 to the extent that any member of the public who is entitled under the provisions of 37 CFR §1.14 to access to, copies of, or information concerning, the prior application may be given similar access to, copies of, or similar information concerning, the other application or applications in the file jacket.

35 USC §120 STATEMENT: In a CPA, no references to the prior application is needed in the first sentence of the specification and none should be submitted. If a sentence referencing the prior application is submitted, it will not be entered. A request for a CPA is the specific reference required by 35 USC §120 and to every application assigned the application number identified in such request, 37 CFR §1.78(a).

1.	\boxtimes	Enter the unentered amendment previously filed on May 13, 2002 under 37 CFR
	_	§1.116 in the prior nonprovisional application.
2.		A Preliminary Amendment is enclosed.
3.		This application is filed by fewer than all the inventors named in the prior application
		37 CFR §1.53(d)(4). DELETE the following inventors(s) named in the prior
		nonprovisional application:
4.		A new Declaration and Power of Attorney is enclosed.
5.		An Information Disclosure Statement (IDS) is enclosed:
		a. PTO-1449 or similar form
		b. Copies of IDS citations
6.	\boxtimes	A return receipt postcard is enclosed.

09/16/2002 AWONDAF1 00000077 023869 09341821

01 FC:131 02 FC:102 740.00 CH 336.00 CH

Docket No.: CV0244

Basic Filing Fee	\$	740					
Before calculating the filing fee, please enter the enclosed Prelim Before calculating the filing fee, please cancel claims .	inary Amendment.						
Filing fee calculation:							
application is hereby reserved. 8. Other:	ade in said parent						
Application No. 09/341,821 in the event of a restriction or ele	The right to elect an invention or species that is different from that elected in paren Application No. 09/341,821 in the event of a restriction or election of species requirement that is identical or substantially similar to that made in said parent						

Basic Fil	ing Fee								\$	740
Multiple Dependent Claim Fee (\$ 280)										
	For	Number Filed		Number Extra			Rate			
Extra Claims	Total Claims	16	-20	0	х	\$	18	=	\$	
	Independent Claims	7	-3	4	х	\$	84	11	\$	336
TOTAL FILING FEE										1,076

Please charge Deposit Account No. 02-3869 in the name of Bristol-Myers Squibb Company in the amount of \$1,076. An additional copy of this paper is enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.16 and §1.17 which may be required in connection with this application, or credit any overpayment, to Deposit Account No. 02-3869 in the name of Bristol-Myers Squibb Company.

Please address all correspondence to:

the present correspondence address for prior Application No.
the address associated with Customer No. 26079, which is currently:
John M. Kilcoyne
Bristol-Myers Squibb Company
Patent Department
100 Headquarters Park Drive

Skillman, NJ 08558

Please direct all telephone calls to the undersigned at the number given below and all telefaxes to (908) 904-2373.

Respectfully submitted,

Date: September 12, 2002

John M. Kilcoyne Attorney for Applicant

Reg. No. 33,100

Tel. No. (908) 904-2372